Inc. (NASDAQ:ETNB), with a market capitalization of $1.14 billion, is a clinical-stage biopharmaceutical company focusing on the development of innovative therapies for the treatment of liver and ...
Pegozafermin. It has two Phase 3 trials: one for MASH and the other for SHTG. See why I continue to rate ETNB stock a buy.
SAN FRANCISCO, Jan. 28, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (“89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on ...
Inc. (NASDAQ:ETNB – Get Free Report) has received an average recommendation of “Moderate Buy” from the seven analysts that ...
It was the best of biotech times, it was the worst of biotech times: One company soars, another stumbles and a third outlines ...
Goldman Sachs, Leerink and BofA acted as joint book running managers for the offering.Invest with Confidence: Follow TipRanks' Top Wall Street ...
(ETNB) stock jumped 40% Monday, stoked by positive data for Akero's (AKRO) drug efruxifermin in the treatment of compensated ...
Inc. (NASDAQ:ETNB – Get Free Report) was the recipient of some unusual options trading on Monday. Traders acquired 2,228 call options on the company. This is an increase of 346% compared to the ...
BioAge scrapped the drug at the center of its $198 million initial public offering last year. Elsewhere, Akero and 89bio raised $600 million combined and Allakos laid off staff.
Investor's Business Daily on MSN3d
Akero Therapeutics Stock Doubles — Pulling 89bio Higher — On Positive MASH StudyAkero Therapeutics nearly doubled Monday — and pulled 89bio shares higher — after the company's treatment for MASH ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback